Yea, I’ve seen the study suggesting that the lipid nanoparticle might concentrate on the ovaries, but this is not the case. The study, specifically the Japanese biodistribution study, found a high concentration of total lipid content in the ovaries, which does not specify lipid nanoparticles alone. So, the more appropriate number to look at is the % of total vaccine administered, and the Japanese study noted that <1% of the vaccine ended up in the ovaries. I covered this more in-depth here:

https://medium.com/microbial-instincts/biodistribution-and-spike-protein-safety-of-mrna-vaccines-an-update-788fe58e39b9?sk=5761d42353e9ccf9763b77c66c952692